Endocrinology Medical News about Acromegaly

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Octreotide Long-Acting Repeatable in Acromegaly: Achieving Optimal Control
The Endocrinologist, 06/19/09

Cook DM - In patients with acromegaly, octreotide LAR is traditionally used as postsurgical therapy in patients with persistent disease. Although surgery remains the first-line treatment option in patients with tumors likely to be completely resected, there is a growing consensus that octreotide LAR could be used as first-line therapy in select patients. Most patients initiating treatment with somatostatin analogs begin with octreotide LAR 20 mg every 28 days. On average, 60% of patients can safely achieve normal GH and insulin-like growth factor-I levels during octreotide LAR therapy, as well as experience significant reduction in pituitary tumor volume.

<< Previous
Peripheral and cerebrovascular atherosclerotic disease in...

Next >>
Overweight in midlife and risk of dementia: A 40-year follow-up...

The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09 Relevance Score: 88%

The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09 Relevance Score: 87%

Discordant Nadir GH After Oral Glucose and IGF-I Levels on Treated Acromegaly: Refining the Biochemical Markers of Mild Disease Activity
Hormone and Metabolic Research, 10/06/09 Relevance Score: 87%

Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients
Clinical Endocrinology, 10/15/09 Relevance Score: 85%

ACTH Deficiency, Higher Doses of Hydrocortisone Replacement, and Radiotherapy Are Independent Predictors of Mortality in Patients with Acromegaly
Journal of Clinical Endocrinology and Metabolism, 10/14/09 Relevance Score: 85%